[go: up one dir, main page]

PL3082831T3 - Kompozycje oparte na metylocyklodekstrynach do leczenia i/lub zapobiegania chorobom poprzez podwyższenie poziomu cholesterolu HDL - Google Patents

Kompozycje oparte na metylocyklodekstrynach do leczenia i/lub zapobiegania chorobom poprzez podwyższenie poziomu cholesterolu HDL

Info

Publication number
PL3082831T3
PL3082831T3 PL14827505T PL14827505T PL3082831T3 PL 3082831 T3 PL3082831 T3 PL 3082831T3 PL 14827505 T PL14827505 T PL 14827505T PL 14827505 T PL14827505 T PL 14827505T PL 3082831 T3 PL3082831 T3 PL 3082831T3
Authority
PL
Poland
Prior art keywords
cyclodextrines
hdl
enhancement
treat
compositions
Prior art date
Application number
PL14827505T
Other languages
English (en)
Inventor
Marc Salome
Daniel Wils
Xavier Parissaux
François MACH
Fabrizio MONTECUCCO
Original Assignee
Roquette Frères
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roquette Frères filed Critical Roquette Frères
Publication of PL3082831T3 publication Critical patent/PL3082831T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • A61K31/724Cyclodextrins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PL14827505T 2013-12-13 2014-12-12 Kompozycje oparte na metylocyklodekstrynach do leczenia i/lub zapobiegania chorobom poprzez podwyższenie poziomu cholesterolu HDL PL3082831T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1362633A FR3014694B1 (fr) 2013-12-13 2013-12-13 Compositions a base de methyl-cyclodextrines pour le traitement et/ou la prevention de maladies par augmentation du taux de cholesterol-hdl
PCT/FR2014/053309 WO2015087016A1 (fr) 2013-12-13 2014-12-12 Compositions a base de methyl-cyclodextrines pour le traitement et/ou la prevention de maladies par augmentation du taux de cholesterol-hdl
EP14827505.0A EP3082831B1 (fr) 2013-12-13 2014-12-12 Compositions a base de methyl-cyclodextrines pour le traitement et/ou la prevention de maladies par augmentation du taux de cholesterol-hdl

Publications (1)

Publication Number Publication Date
PL3082831T3 true PL3082831T3 (pl) 2021-06-28

Family

ID=50424476

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14827505T PL3082831T3 (pl) 2013-12-13 2014-12-12 Kompozycje oparte na metylocyklodekstrynach do leczenia i/lub zapobiegania chorobom poprzez podwyższenie poziomu cholesterolu HDL

Country Status (15)

Country Link
US (2) US10022392B2 (pl)
EP (2) EP3581188A1 (pl)
JP (2) JP6322289B2 (pl)
KR (3) KR20160088874A (pl)
CN (2) CN105792833B (pl)
AU (2) AU2014363270B2 (pl)
BR (1) BR112016013481A2 (pl)
CA (2) CA2930489C (pl)
DK (1) DK3082831T3 (pl)
ES (1) ES2859609T3 (pl)
FR (1) FR3014694B1 (pl)
MX (2) MX388947B (pl)
PL (1) PL3082831T3 (pl)
RU (1) RU2677889C1 (pl)
WO (2) WO2015087017A1 (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013296170A1 (en) 2012-08-03 2015-03-12 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Cyclodextrin for the treatment of lysosomal storage diseases
WO2016201137A1 (en) * 2015-06-10 2016-12-15 Vtesse, Inc. Hydroxypropyl beta-cyclodextrin compositions and methods
FR3042501B1 (fr) * 2015-10-16 2017-11-03 Roquette Freres Nouvelles cyclodextrines methylees et leurs procedes de preparation
US20200000840A1 (en) * 2016-03-20 2020-01-02 Asdera Llc Use of cyclodextrins to reduce endocytosis in malignant and neurodegenerative disorders
CA3030142A1 (en) * 2016-07-08 2018-01-11 Ranedis Pharmaceuticals, Llc Compositions and methods of treating and/or preventing lysosomal storage diseases and other monogenetic metabolic diseases
KR101906578B1 (ko) * 2017-07-28 2018-10-10 경북대학교 산학협력단 사이클로덱스트린 및 vegf 과발현 줄기세포를 유효성분으로 포함하는 퇴행성 신경질환의 예방 또는 치료용 약학적 조성물
KR20200107927A (ko) 2017-09-28 2020-09-16 아스데라 엘엘씨 인지질 조절장애를 수반하는 질환 및 장애에서의 시클로덱스트린의 용도
CN107982546A (zh) * 2017-12-05 2018-05-04 中国药科大学 基于主客体相互作用的酸敏感超分子纳米粒及其应用
US12089930B2 (en) 2018-03-05 2024-09-17 Marquette University Method and apparatus for non-invasive hemoglobin level prediction
CN108342473A (zh) * 2018-04-13 2018-07-31 东华大学 一种用于检测血脂代谢相关基因abcg1甲基化的试剂盒
FR3083234B1 (fr) * 2018-06-29 2020-11-27 Roquette Freres Nouvelles hydroxypropyl-beta-cyclodextrines et leurs procedes de preparation
SG11202013126QA (en) * 2018-06-29 2021-02-25 Roquette Freres NOVEL HYDROXYPROPYL-ß-CYCLODEXTRIN AND PROCESS FOR THE PRODUCTION THEREOF
KR20210084480A (ko) * 2018-10-29 2021-07-07 싸이클로 테라퓨틱스, 아이엔씨. 알츠하이머 질환을 치료하는 방법
CA3125554A1 (en) * 2019-01-03 2020-07-09 Underdog Pharmaceuticals, Inc. Cyclodextrin dimers, compositions thereof, and uses thereof
US11446325B2 (en) * 2020-09-30 2022-09-20 Cyclolab Cyclodextrin Research And Development Laboratory Ltd. Cyclodextrin derivatives in the treatment or prevention of lysosomal neurodegenerative diseases
FR3115682B1 (fr) * 2020-11-05 2023-02-24 Roquette Freres Compositions à base de méthyl-cyclodextrines pour le traitement et/ou la prévention de la stéatose hépatique
AU2023220047A1 (en) 2022-02-18 2024-09-19 Beren Therapeutics P.B.C. Compositions of hydroxypropyl-beta-cyclodextrin and methods of purifying the same
WO2023156970A1 (en) * 2022-02-18 2023-08-24 Beren Therapeutics P.B.C. Treatment of hypertriglyceridemia with 2-hydroxypropyl-beta-cyclodextrin

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62265230A (ja) * 1986-05-12 1987-11-18 Kao Corp 高脂血症治療・予防剤
BE1006873A6 (nl) * 1993-03-26 1995-01-10 Merkus Franciscus W H M Toedieningsformulering voor nasale insuline toediening.
NZ505761A (en) 1998-01-28 2003-08-29 Warner Lambert Co Method for treating alzheimer's disease using plasma-triglceride level-lowering agents or agents that interfer with cholesterol ester synthesis
JP2003514925A (ja) 1999-11-12 2003-04-22 ピサ・アンド・ピサ・エルエルシー ベータ−シクロデキストリン及び関連化合物の部分メチルエーテルの結晶性混合物
WO2001080715A2 (en) * 2000-04-21 2001-11-01 The Trustees Of Columbia University In The City Of New York Methods for identifying compounds useful for preventing acute clinical vascular events in a subject
AUPR178300A0 (en) * 2000-11-29 2000-12-21 Heart Research Institute Ltd., The Cyclodextrins and reversal of atherosclerosis
TW200307011A (en) * 2002-04-18 2003-12-01 Chugai Pharmaceutical Co Ltd Hyaluronic acid modifier
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
EP1781305A2 (en) * 2004-08-13 2007-05-09 Angiotech International Ag Compositions and methods using hyaluronic acid and hyaluronidase inhibitors
GB0421176D0 (en) * 2004-09-23 2004-10-27 Poston Robin Treatment of atherosclerosis
US9034846B2 (en) * 2004-10-10 2015-05-19 Universite De Liege Use of cyclodextrin for treatment and prevention of bronchial inflammatory diseases
EP1655034A1 (en) 2004-10-10 2006-05-10 Université de Liège Use of cyclodextrin for treatment and prevention of bronchial inflammatory diseases.
US7879821B2 (en) * 2006-01-26 2011-02-01 University Of Medicine And Dentistry Of New Jersey Method for modulating inflammatory responses by altering plasma lipid levels
TW201006463A (en) * 2008-06-26 2010-02-16 Merz Pharma Gmbh & Co Kgaa Pharmaceutical compositions comprising aminocyclohexane derivatives

Also Published As

Publication number Publication date
DK3082831T3 (da) 2021-04-12
FR3014694B1 (fr) 2016-11-11
US20180207198A1 (en) 2018-07-26
JP2018123153A (ja) 2018-08-09
RU2677889C1 (ru) 2019-01-22
AU2020200500B2 (en) 2021-08-12
CN110123831A (zh) 2019-08-16
JP6322289B2 (ja) 2018-05-09
MX2016007658A (es) 2016-09-26
CA2930489C (fr) 2023-01-17
US20160361344A1 (en) 2016-12-15
MX381039B (es) 2025-03-12
MX388947B (es) 2025-03-19
CN105792833B (zh) 2021-06-25
CN105792833A (zh) 2016-07-20
KR20210158867A (ko) 2021-12-31
CA2930489A1 (fr) 2015-06-18
KR20210072129A (ko) 2021-06-16
AU2020200500A1 (en) 2020-02-13
KR102463677B1 (ko) 2022-11-07
CA3180528A1 (fr) 2015-06-18
BR112016013481A2 (pt) 2018-01-16
US11266680B2 (en) 2022-03-08
US10022392B2 (en) 2018-07-17
AU2014363270B2 (en) 2020-03-12
WO2015087017A1 (fr) 2015-06-18
JP2017500310A (ja) 2017-01-05
EP3082831A1 (fr) 2016-10-26
KR20160088874A (ko) 2016-07-26
EP3581188A1 (fr) 2019-12-18
KR102453643B1 (ko) 2022-10-12
EP3082831B1 (fr) 2021-01-06
ES2859609T3 (es) 2021-10-04
FR3014694A1 (fr) 2015-06-19
AU2014363270A1 (en) 2016-05-19
WO2015087016A1 (fr) 2015-06-18

Similar Documents

Publication Publication Date Title
PL3082831T3 (pl) Kompozycje oparte na metylocyklodekstrynach do leczenia i/lub zapobiegania chorobom poprzez podwyższenie poziomu cholesterolu HDL
IL273090B (en) Methods and preparations for the treatment of cancer
EP3024457A4 (en) Compositions to improve the therapeutic benefit of bisantrene
IL245408B (en) Converted benzamides for the treatment of arthropods
IL244677B (en) Effective preparations for the treatment of kit-related disorders
IL246252A0 (en) Diaminopyrimidyl derivative compounds, their compositions and methods of treatment
SG11201601412XA (en) Compositions and methods for the treatment of presbyopia
HUE051373T2 (hu) Készítmények MPSI kezelésére
EP3169784A4 (en) Organic compositions to treat apoc3-related diseases
SG11201506805QA (en) Organic compositions to treat epas1-related diseases
GB201404403D0 (en) Compositions and methods relating to the treatment of diseases
SG10201705899XA (en) Prevention & treatment of neuropathy
PL2968478T3 (pl) Kompozycje i sposoby do leczenia karboksyhemoglobinemii
EP3010504A4 (en) Methods and compositions to treat cancer
ZA201506392B (en) Compositions and methods including celecoxib and plumbagin relating to treatment of cancer
ZA201509360B (en) Compositions and methods for treatment of stroke
PL3079684T3 (pl) Kompozycje i sposoby do leczenia chorób związanych z układem renina-angiotensyna
SG11201509640RA (en) Use of an isopropanol-containing solution to combat calciviridae
PT3041488T (pt) Composições de mel
ZA201404930B (en) Plant treatment composition
AU2013903871A0 (en) Compositions for treating skin conditions